Sugi Predict

Sugi Predict / Compounds / SCHEMBL5533637

SCHEMBL5533637

SCHEMBL5533637

NC(CN1CCOCC1)C(=O)O

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 4/20 0.61
▸ ANPEP P15144 1/20 0.56
▸ USP2 O75604 1/20 0.54
▸ KDM4E B2RXH2 3/20 0.50
▸ HSD17B10 Q99714 2/20 0.50
▸ GLA P06280 1/20 0.47
▸ LMNA P02545 2/20 0.45
▸ HIF1A Q16665 2/20 0.45
▸ MAPT P10636 1/20 0.45
▸ HTT P42858 1/20 0.45
▸ RAB9A P51151 1/20 0.45
▸ ATM Q13315 1/20 0.45
▸ ALOX15 P16050 1/20 0.44
▸ TSHR P16473 1/20 0.44
▸ MEN1 O00255 2/20 0.43
▸ KMT2A Q03164 2/20 0.43
▸ NPC1 O15118 1/20 0.42
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ CYP1A2 P05177 2/20 0.40
▸ GRM5 P41594 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15049655 1.00 ALDH1A1 (0.61) ALDH1A1ANPEPUSP2KDM4EHSD17B10
SCHEMBL7288389 0.83 ANPEP (0.56) ALDH1A1ANPEPUSP2KDM4EHSD17B10
SCHEMBL25661087 0.83 DPP7 (0.52) ALDH1A1ANPEPMAPTATMALOX15
SCHEMBL5322593 0.83 DPP7 (0.52) ALDH1A1ANPEPMAPTATMALOX15
SCHEMBL15826790 0.82 GLA (0.55) ALDH1A1ANPEPKDM4EHSD17B10GLA
SCHEMBL1889261 0.82 GLA (0.55) ALDH1A1ANPEPKDM4EHSD17B10GLA
SCHEMBL11604652 0.81 ALDH1A1 (0.63) ALDH1A1ANPEPUSP2KDM4EHSD17B10
SCHEMBL2065181 0.81 DPP7 (0.55) ALDH1A1ANPEPHSD17B10MAPTATM
SCHEMBL1176730 0.81 DPP7 (0.55) ALDH1A1ANPEPHSD17B10MAPTATM
SCHEMBL384886 0.81 DPP7 (0.55) ALDH1A1ANPEPHSD17B10MAPTATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250296915-A1 NOVEL AMINO ACID DERIVATIVES PEPTIDREAM INC (JP) 2025-09-25 — — US claimed
US-20260116923-A1 CYCLIC PEPTIDE IL-1BETA TRAP FOR THE TREATMENT OF ATHEROSCLEROSIS AND INFLAMMATORY DISORDERS MERCK SHARP & DOHME LLC (US) 2026-04-30 — — US disclosed
EP-4724459-A1 PEPTIDE COMPOSITIONS TARGETING GLYPICAN-3 AND USES THEREOF Peptidream Inc (JP) 2026-04-15 — — EP disclosed
EP-4724457-A2 RADIOPHARMACEUTICAL COMPOSITIONS TARGETING GLYPICAN-3 AND USES THEREOF Rayzebio, Inc. (US) 2026-04-15 — — EP disclosed
US-20260070945-A1 MACROCYCLIC IMMUNOMODULATORS BRISTOL-MYERS SQUIBB COMPANY 2026-03-12 — — US disclosed
US-20260022142-A1 MACROCYCLIC IMMUNOMODULATORS BRISTOL MYERS SQUIBB CO (US) 2026-01-22 — — US disclosed
WO-2024254339-A9 RADIOPHARMACEUTICAL COMPOSITIONS TARGETING GLYPICAN-3 AND USES THEREOF RAYZEBIO, INC. (US) 2025-10-16 — — WO disclosed
US-20250296915-A1 NOVEL AMINO ACID DERIVATIVES PEPTIDREAM INC (JP) 2025-09-25 — — US disclosed
US-20250277012-A1 CONJUGATED HEPCIDIN MIMETICS PROTAGONIST THERAPEUTICS, INC. 2025-09-04 — — US disclosed
US-20250250299-A1 MACROCYCLIC IMMUNOMODULATORS BRISTOL-MYERS SQUIBB COMPANY 2025-08-07 — — US disclosed
US-8748575-B2 Therapeutic peptides COMBIMAB, INC. (US) 2014-06-10 — — US disclosed
US-20140038881-A1 Therapeutic Peptides COMBIMAB, INC (US) 2014-02-06 — — US disclosed
EP-2605786-A2 THERAPEUTIC PEPTIDES Combimab, Inc. (US) 2013-06-26 — — EP disclosed
WO-2011156453-A2 THERAPEUTIC PEPTIDES COMBIMAB, INC. (US) 2011-12-15 — — WO disclosed
WO-2007056596-A2 PHOSPHORAMIDATE DERIVATIVES OF FAU WAYNE STATE UNIVERSITY (US) 2007-05-18 — — WO disclosed
WO-2005112922-A9 BENZAMIDE COMPOUNDS SAMARITAN PHARMACEUTICALS (US) 2006-03-09 — — WO disclosed
EP-1631289-A2 ANTI-HIV BENZAMIDE COMPOUNDS Samaritan Pharmaceuticals, Inc. (US) 2006-03-08 — — EP disclosed
EP-1628660-A2 METHODS AND COMPOSITIONS FOR MODULATING SERUM CORTISOL LEVELS Samaritan Pharmaceuticals, Inc. (US) 2006-03-01 — — EP disclosed
WO-2005000205-A2 METHODS AND COMPOSITIONS FOR MODULATING SERUM CORTISOL LEVELS SAMARITAN PHARMACEUTICALS, INC. (US) 2005-01-06 — — WO disclosed
WO-2004108076-A2 ANTI-HIV BENZAMIDE COMPOUNDS SAMARITAN PHARMACEUTICALS, INC. (US) 2004-12-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250296915-A1 NOVEL AMINO ACID DERIVATIVES DNPEP, BCAT1, ANPEP ALDH1A1 4626/4885ANPEP 3/4885USP2 2435/4885
US-20260022142-A1 MACROCYCLIC IMMUNOMODULATORS CD274, PDCD1LG2, PDCD1 ALDH1A1 746/4885ANPEP 3181/4885USP2 4098/4885
US-20260070945-A1 MACROCYCLIC IMMUNOMODULATORS CD274, PDCD1, PDCD1LG2 ALDH1A1 476/4885ANPEP 1901/4885USP2 4268/4885
US-20250277012-A1 CONJUGATED HEPCIDIN MIMETICS HAMP, VIP, HDGF ALDH1A1 4194/4885ANPEP 35/4885USP2 2897/4885
US-20260116923-A1 CYCLIC PEPTIDE IL-1BETA TRAP FOR THE TREATMENT OF ATHEROSCLEROSIS AND INFLAMMATORY DISORDERS IL1A, IL1B, IL1RN ALDH1A1 3103/4885ANPEP 559/4885USP2 3437/4885
US-20250250299-A1 MACROCYCLIC IMMUNOMODULATORS CD274, PDCD1LG2, PDCD1 ALDH1A1 1254/4885ANPEP 3305/4885USP2 3536/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.